ReviewClinical and experimental immunology2017
Intracellular signalling pathways: targets to reverse immunosenescence.
Review in Clinical and experimental immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 53 citations in OpenAlex.
- Aging and cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- Rejuvenation alleviates prolonged postsurgical pain in aging mice by mitigating inflammaging.Pain · 2025Article
- Review of evidence linking exposure to environmental stressors and associated alterations in the dynamics of immunosenescence (ISC) with the global increase in multiple sclerosis (MS).Immunity & ageing : I & A · 2024Review
- The Impact of Immune System Aging on Infectious Diseases.Microorganisms · 2024Review
- Considerations and Approaches for Cancer Immunotherapy in the Aging Host.Cancer immunology research · 2023Review
- Review
- Loneliness, Depression, and Genetics in the Elderly: Prognostic Factors of a Worse Health Condition?International journal of environmental research and public health · 2022Article
- Immunomodulatory and Antiaging Mechanisms of Resveratrol, Rapamycin, and Metformin: Focus on mTOR and AMPK Signaling Networks.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Immunosenescence and COVID-19.Mechanisms of ageing and development · 2022Review
- Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?Frontiers in oncology · 2022Review
- Vaccine-induced ICOSCell reports. Medicine · 2021Article
- The GSK3β-β-catenin-TCF1 pathway improves naive T cell activation in old adults by upregulating miR-181a.NPJ aging and mechanisms of disease · 2021Article
- Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.Frontiers in pharmacology · 2021Review
- The dual role of the immune system in the course of COVID-19. The fatal impact of the aging immune system.Central-European journal of immunology · 2021Article
- Older adults: panoramic view on the COVID-19 vaccination.AIMS public health · 2021Review
- Immunosenescence in Childhood Cancer Survivors and in Elderly: A Comparison and Implication for Risk Stratification.Frontiers in aging · 2021Review
- Allele-Specific Transcript Abundance: A Pilot Study in Healthy Centenarians.The journals of gerontology. Series A, Biological sciences and medical sciences · 2020Article
- The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy.Molecular cancer · 2020Review
- Biological Aging and the Cellular Pathogenesis of Huntington's Disease.Journal of Huntington's disease · 2020Review
- Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.Experimental gerontology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ageing is a very complex process, the result of the dysregulation of multiple systems interacting in many ways. A prominent change occurring with ageing is related to the architecture and functioning of the immune system, viewed commonly as detrimental and termed 'immunosenescence'. However, age-associated changes may also lead to increased function in certain respects, which can be viewed as adaptive. None the less, on balance it is well-recognized that immunosenescence is accompanied by the low-grade inflammation observed commonly in elderly people, which has been dubbed 'inflamm-ageing'. The exact cause and significance of all these changes is not clear, but there is a consensus that they are related to the occurrence of chronic non-infectious age-associated disease, as well as increased susceptibility to infections. Alterations to immune cell signalling may be a prominent cause of malfunctioning immunity. Emerging attempts to reverse immunosenescence have recently targeted the signalling pathways in various different cell types of the immune system. Here, we review and discuss alterations in the signalling pathways of immune cells with ageing and consider current targets and means to modulate altered functions. We discuss the potential dangers as well as the benefits of these interventions, and consider future approaches to this problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.